Wall Street Close: It is vaccine hopes vs lockdown pessimism, stocks sink

The Dow Jones Industrial Average dropped 345.91 points, or 1.16%
The S&P 500 fell 41.81 points, or 1.16%, to 3,567.72.
he Nasdaq Composite lost 97.74 points, or 0.82%.

US stocks sank on Wednesday and took the three major indexes back into the red.

There was a positive start to the day, however, with Pfizer Inc PFE and its German partner BioNTech BNTX revealing a 95% success rate at the conclusion of their COVID-19 vaccine trial.

This came on the heels of Moderna Inc MRNA announcement of a similar rate of success on Monday with its own vaccine candidate.

''Results from the Oxford-AstraZeneca trial is expected soon so the good news flow may still have legs yet,'' analysts at ANZ bank noted, but said hurdles, such as ''further safety testing, approval, the scale of manufacture, and distribution still need to be cleared.''

''Nonetheless, the world and its policymakers are watching and waiting with bated breath.''

However, there was a sense of concern as the news of the US death rate breaking 250,000 circulated and as global new infections also soared to record levels.

Investors are concerned that increased restrictions will have to be implemented as the US economy struggles to recover from the recession.

Consequently, the Dow Jones Industrial Average dropped 345.91 points, or 1.16%, to 29,437.44, the S&P 500 fell 41.81 points, or 1.16%, to 3,567.72 and the Nasdaq Composite lost 97.74 points, or 0.82%, to 11,801.60.

Meanwhile, the third-quarter reporting season has reached the last leg.

468 of the companies in the S&P 500 have already reported. Of those, 84.4% have surprised consensus to the upside, according to Refinitiv.

US data a bright spot

US October housing starts rose 4.9% MoM to 1530k saar.

''They are now almost back at pre-COVID levels (1617k) marking a V-shaped recovery. Demand for single-family homes remains very strong,'' analysts at ANZ explained.

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.